4Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, et al. Myopic choroidal neovascularization: a 10- year follow-up [ J ]. Ophthalmology,2003,110 ( 7 ) : 1297-1305.
5Neelam K, Cheung CM, Ohno-Matsui K, Lai TY, Wong TY. Cho- roidal neovascularization in pathological myopia[ J]. Pvg Retin Eye Res ,2012,31 (5) :495-525.
6Lala C, Framme C, Wolf-Sctmurrbusch UE, Wolf S. Three-year results of visual outcome with disease activity-guided ranibi- zumab algorithm for the treatment of exudative age-related mac- ular degeneration[ J]. Acta Ophthalmo1,2013,91 ( 6 ) :526-530.
8Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor anti- gen binding fragment, as therapy for neovascular age-related macular degeneration [ J ]. Retina,2006,26 ( 8 ) : 859-870.
9Silva RM, Ruiz-Moreno JM, Nascimento J, Carneiro A, Rosa P, Barbosaa A, et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization [ J ]. Reti- na,2008,28(8) :1117-1123.
10Bottoni F, Tflanus M. The natural history of juxtafoveal and sub- foveal choroidal neovascularization in high myopia [ J ]. Int Oph- tkamo1,2001,24 ( 5 ) :249-255.
